Global Amodiaquine Market Size By Type (Type I, Type II), By Application (Antimalarial Drugs, Anti-Inflammatory Drugs), By Region, And Segment Forecasts, 2023 to 2032

The Global Amodiaquine Market was valued at USD 527.6 million in 2023 and is projected to reach USD 874.3 million by 2031, growing at a CAGR of 6.8% during the forecast period (2023–2031). Amodiaquine, an antimalarial medication primarily used in the treatment and prevention of Plasmodium falciparum malaria, continues to be a vital component in global malaria control programs. Its affordability, efficacy, and compatibility with artemisinin-based combination therapies (ACTs) have contributed significantly to market expansion. Increasing incidences of malaria in tropical regions, international funding for malaria eradication, and growing public health initiatives are further fueling market growth.

Drivers:

1. Rising Prevalence of Malaria in Endemic Regions:

High malaria burden in sub-Saharan Africa, Southeast Asia, and parts of South America is driving demand for effective antimalarial drugs, including amodiaquine, especially in pediatric and rural populations.

2. Support from Global Health Organizations:

Organizations such as the WHO, UNICEF, and Global Fund are promoting the use of ACTs, where amodiaquine is combined with artesunate or other drugs. Their procurement and distribution efforts are substantially contributing to market expansion.

3. Growing Use in Seasonal Malaria Chemoprevention (SMC):

Amodiaquine’s effectiveness in SMC programs, especially for children under 5, is increasing its usage. Government-led campaigns and donor-funded distribution programs are expanding the drug’s footprint.

Restraints:

1. Adverse Drug Reactions and Contraindications:

Although generally safe when properly administered, amodiaquine is associated with rare but serious side effects such as hepatotoxicity and agranulocytosis, which may deter prescribers in certain healthcare settings.

2. Emergence of Drug-Resistant Strains:

Reports of Plasmodium falciparum strains developing resistance to amodiaquine in parts of West Africa pose a potential threat to long-term market sustainability, urging the need for monitoring and alternative treatment strategies.

Opportunity:

1. Expansion of Malaria Elimination Programs in Emerging Economies:

Government efforts in Asia-Pacific and Africa to scale up malaria prevention and treatment strategies present lucrative opportunities for market players.

2. Innovation in Formulation and Distribution:

Development of fixed-dose combinations, pediatric dispersible tablets, and longer shelf-life formulations are expected to open up new markets and reduce logistical challenges in remote regions.

Market by System Type Insights:

By formulation, Tablet form accounted for the largest market share in 2023 due to its stability, ease of distribution, and cost-effectiveness in mass treatment campaigns. However, Dispersible Tablets are anticipated to witness faster growth, driven by their preference in pediatric populations and ease of administration without requiring water.

Market by End-use Insights:

In 2023, the Public Health Sector emerged as the largest end-use segment, backed by extensive use in government-run and donor-funded malaria programs. The Private Healthcare Sector is expected to grow steadily due to increasing awareness, self-medication trends, and access to over-the-counter treatments in low-income and rural settings.

Market by Regional Insights:

Africa dominated the global market in 2023, accounting for over 60% of total revenue. This is attributed to the high malaria incidence and widespread implementation of SMC and ACT protocols. Asia-Pacific is projected to be the fastest-growing region, driven by intensified vector control efforts, improved diagnosis, and national malaria elimination plans in countries like India, Cambodia, and Myanmar.

Competitive Scenario:

Key players in the Global Amodiaquine Market include Cipla Inc., Sanofi S.A., Ipca Laboratories Ltd., Novartis AG, Macleods Pharmaceuticals Ltd., Guilin Pharmaceutical Co. Ltd., Mylan N.V., Ajanta Pharma, and Zydus Lifesciences. These companies are engaged in WHO-prequalified manufacturing, regional partnerships, and development of novel fixed-dose combinations to enhance therapeutic compliance.

Key Market Developments:

In 2023, Cipla expanded its production capacity for amodiaquine-based combinations in response to increased demand from African nations.

In 2024, Sanofi announced the distribution of over 50 million doses of ASAQ (artesunate–amodiaquine) in collaboration with international health organizations.

In 2025, Macleods Pharmaceuticals launched dispersible amodiaquine tablets targeting pediatric patients in Asia-Pacific under SMC initiatives.

Scope of Work – Global Amodiaquine Market

FAQs

1. What is the current market size of the Global Amodiaquine Market?

The market was valued at USD 527.6 million in 2023.

2. What is the major growth driver of the Global Amodiaquine Market?

The major growth driver is the increasing prevalence of malaria in endemic regions and strong support from global health initiatives.

3. Which is the largest region during the forecast period in the Global Amodiaquine Market?

Africa is the largest regional market, driven by high malaria incidence and public sector procurement.

4. Which segment accounted for the largest market share in the Global Amodiaquine Market?

The Tablet formulation segment accounted for the largest market share in 2023.

5. Who are the key market players in the Global Amodiaquine Market?

Key players include Cipla Inc., Sanofi S.A., Ipca Laboratories Ltd., Novartis AG, and Macleods Pharmaceuticals Ltd.